Molecular Medicine | Molecular Medicine Reports …

Integrative Molecular Medicine (IMM) Online ISSN: 2056-6360 University College London Cancer Treatment Centers of America

Integrative Molecular Medicine (IMM) is a peer-reviewed, online open access journal dedicated to a new research discipline at the interface between clinical research and basic biology. We aim to publish articles that broadly enlighten the biomedicine research community by providing an insight on breakthrough discoveries in basic and clinical medicinal research, thereby lending a strong impetus to this important and rapidly developing field and helping to forge new links between clinicians and molecular biologists. Integrative Molecular Medicine highlights ongoing integrative basic and clinical biomedicines covering fields of biology and medicine.As such the following qualities are essential in any article published by the journal: scientific credibility and rigour, and coherence and clarity in the writing. Contributions do not need to be novel as confirmatory and replication studies will be considered, however the article must present new findings, which could include the reporting of negative findings.

IMM provides a new platform for all researchers, scientists, scholars, students to publish their research work and update the latest research information.Integrative Molecular Medicine publishes research articles as full-length research papers and short reports. In addition, the journal publishes editorials and review articles in innovative formats that target a broad and non-specialized audience.

Journal will accept article from the following topics are integrative medical fields including biochemistry, molecular and cell biology, biotechnology, genetics, physiology, endocrinology, signal transduction, cell proliferation, differentiation and development, stem cells and regenerative medicine apoptosis, gene expression, pathology, metabolic disease, genomics, transcriptomics, proteomics, metabolomics of disease, systems medicine, brain disease, cardiovascular biology, diabetes, obesity, osteoporosis, nutrition, pharmacology, toxicology, cancer biology and oncology, epidemiology, genetic medicine, and other medicine-related topics.

IMM welcomes direct submissions of manuscripts from authors. You can submit your manuscript to: submissions@oatext.com; alternatively to: yamaguchi@oatext.com

I graduated as an MD at Lviv State Medical University (Ukraine) in 1983 with a great passion to become a surgeon in oncology. Thinking that a PhD in experimental oncology would help to realize my dream, I obtained my doctorate at the Institute of Experimental Oncology, National Academy of Sciences of Ukraine in 1987. A fellowship from the International Agency for Research on Cancer (IARC) took me even further from clinical oncology and also from Ukraine. I arrived in London on the first wave of perestroika and began my post-doctoral training in Jim Woodgett's laboratory at the Ludwig Institute for Cancer Research (UCL Branch). Subsequently, I worked in Mike Waterfield's laboratory at the same Institute studying signal transduction via the PI3 kinase pathway. In 1996, I started my own group at the Ludwig Institute for Cancer Research, focusing on the regulation of growth via the S6 kinase pathway. Since 2003, I have been a Professor in the Department of Biochemistry at UCL now renamed Structural and Molecular Biology, where I have an active research group working on signal transduction and cellular metabolism in health and disease. I have a strong research (113 papers in peer-reviewed journals, H-Index 52) and patent (10 world-wide patents) portfolio and run two drug discovery programs aimed at developing small molecule inhibitors, targeting ribosomal S6 kinase and Aurora A kinase.

Dr. Alvarez, a native of Argentina, joined CTCA in October 2014 to lead the companys global focus on cancer research. He is internationally known for his contribution to breast cancer multidisciplinary management, inflammatory breast cancer, and discovery and monitoring of minimal residual disease in solid tumors. As a medical oncologist, he has focused his clinical career the past two decades on treating patients with the most difficult cases of breast cancer. Prior to joining CTCA, Dr. Alvarez served for five years as an Assistant Professor in the University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology, Division of Cancer Medicine in Houston, Tx. He also served as Assistant Professor at The Morgan Welch Inflammatory Breast Cancer Research Program. His additional experience includes teaching at the Department of Pathology and the Department of Internal Medicine, Universidad Nacional de La Plata, Argentina. He served as Chief, Oncology Section, Hospital Ramon Carrillo - San Carlos de Bariloche, Rio Negro, Argentina, and Instructor, Oncology Consultants P.A., Houston, Tx. He was Secretary of Clinical Oncology Section, School of Oncology, Fundacion Jose Maria Mainetti, Centro Oncologico de Excelencia, Gonnet, Argentina; and Member, Centro Oncologico de Excelencia, Gonnet.

Dr. Alvarez received his medical degree from Universidad Nacional de La Plata - Facultad de Medicina, Argentina. He completed his residency in internal medicine and medical oncology at Centro Oncologico de Excelencia - Gonnet, Argentina. Following completion of his medical oncology training, he pursued additional training in Clinical Pathology to further study molecular diagnostic and serve as Instructor at the Pathology Department with Dr. Pedro Laguens at the Universidad Nacional de La Plata. He also participated in multiple research activities and attended multiple grand rounds with Professors Jose Maria Mainetti and Alberto Luchina, and with several others became leaders in Argentinean oncology. Following his training in Argentina, he moved to Houston to pursue a medical residency in internal medicine at The University of Texas at Houston, and completed a fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center, Houston, TX. He earned a masters degree in cancer biology from the Graduate School of Biomedical Sciences at Houston. Dr. Alvarez has received numerous professional awards for his work in cancer research, including T-32 NIH CA009666 in 2006, Award of Excellence in Cancer Research by Texas Medical Society of Oncology in 2008, and the Susan Papizan Dolan Fellowship in Breast Cancer Research in 2008. He has participated in nearly $5 million in research grants and contracts with multiple clinical studies, including several Phase II Investigator Initiated Studies, since 2009 alone.

In 2014, he was Principal Investigator in a study related to monitoring minimal residual disease in locally advanced breast cancer and inflammatory breast cancer by detecting circulating tumor cells. The goal of this study, funded by Sister Institution Fund Network as part of the Global Academy Program Department at MD Anderson, is to identify molecular markers of breast cancer tumor recurrence. This clinical trial is currently active in the U.S., as well as in five academic Institutions across the world, including: INCan in Mexico, INEM in Peru, Clnica Alemana in Santiago de Chile, Barretos Hosptial in Brasil, and University of Oslo in Norway. Dr. Alvarez has authored more than 50 articles, abstracts and book chapters and is a frequent presenter at international oncology conferences. His professional memberships include: American Society of Clinical Oncology (ASCO,) American College of Physicians (ACP), American Society of Hematology (ASH), American Association of Cancer Research (AACR), and the Society of Clinical Research Associates (SOCRA). He was a founding member of Grupo de Estudio Tratamiento e Investigacion del Cancer del Sur (GETICS) in Argentina in 1996.

Hiromichi Nakadate Evrim Kurtoglu Shota Shirasaki Shigeru Aomura

Research Article-Integrative Molecular Medicine (IMM)

August 06, 2016

Taishi Koganemaru Koji Hori Misa Hosoi Kimiko Konishi Mitsugu Hachisu Hiroi Tomioka Masayuki Tani Yuka Kitajima Atsuko Inamoto

Case Report-Integrative Molecular Medicine (IMM)

August 09, 2016

Margaret Simonian

Editorial-Integrative Molecular Medicine (IMM)

August 09, 2016

Koji Wakame Akifumi Nakata Keisuke Sato Takehito Miura Anil.D.Kulkarni Marie-Francoise Doursout Alamelu Sundersan Ken-Ich Komatsu

Research Article-Integrative Molecular Medicine (IMM)

August 10, 2016

Veronica J. James Mark McGovern Peihong Wu Boyang Chang Yankeng Wu

Mini Review-Integrative Molecular Medicine (IMM)

August 18, 2016

Josh Hiller Celeste Vallejo Leo Betthauser James Keesling

Research Article-Integrative Molecular Medicine (IMM)

August 19, 2016

Gregory Lee

Research Article-Integrative Molecular Medicine (IMM)

August 25, 2016

Yoko Takai Asuka Matsuo Zhiwei Qiao Tadashi Kondo

Research Article-Integrative Molecular Medicine (IMM)

August 26, 2016

Oxenkrug G Cornicelli J van der Hart M Roeser J Summergrad P

Research Article-Integrative Molecular Medicine (IMM)

August 29, 2016

Cristina Daneri-Becerra Mario D. Galigniana

Research Article-Integrative Molecular Medicine (IMM)

August 22, 2016

Nepton Sheik Khoni GhazalehShoja E Razavi Himakshi Sharma

Research Article-Integrative Molecular Medicine (IMM)

August 22, 2016

Charles J. Malemud

Research Article-Integrative Molecular Medicine (IMM)

September 05, 2016

Nepton Sheik Khoni Abdul Rahman El Kinge Abdul Rahman El Kinge

Perspective-Integrative Molecular Medicine (IMM)

August 30, 2016

Akio Sugitachi Naoko Takahashi Yoshimori Takamori

Research Article-Integrative Molecular Medicine (IMM)

May 12, 2016

Alexander P Lykov Elena P Trifonova Olga V Sazonova Elena V Zonova

Research Article-Integrative Molecular Medicine (IMM)

May 14, 2016

Shigeru Aomura Hiromichi Nakadate Yuma Kaneko Akiyoshi Nishimura Remy Willinger

Research Article-Integrative Molecular Medicine (IMM)

May 18, 2016

Mitsumi Arito Hiroyuki Mitsui Manae S Kurokawa Kazuo Yudoh Toshikazu Kamada Hisateru Niki Tomohiro Kato

Research Article-Integrative Molecular Medicine (IMM)

May 26, 2016

Zen Kouchi

Research Article-Integrative Molecular Medicine (IMM)

May 27, 2016

Yoshimitsu Kiriyama Kunihiko Kasai Katsuhito Kino Hiromi Nochi

Research Article-Integrative Molecular Medicine (IMM)

June 10, 2016

Hisako Nakagawa Tadaaki Miyazaki

Research Article-Integrative Molecular Medicine (IMM)

June 13, 2016

Yoshikazu Hirasawa Hisayo Yokoyama Nooshin Naghavi Yoshihiro Yamashina Ryosuke Takeda Akemi Ota Daiki Imai Tomoaki Morioka Masanori Emoto Kazunobu Okazaki

Research Article-Integrative Molecular Medicine (IMM)

June 17, 2016

Toshihisa Ishikawa Masaharu Shinkai Takeshi Kaneko

Mini Review-Integrative Molecular Medicine (IMM)

June 22, 2016

Osman A Hamour Eman M.Fallatah Rawan O. Alshehri Zain A. Alshareef Halah F.AL-Enizi

Research Article-Integrative Molecular Medicine (IMM)

June 23, 2016

Kazuyuki Matsushima Mika Suematsu Chie Mifude Kuniyoshi Kaseda

Research Article-Integrative Molecular Medicine (IMM)

June 24, 2016

A. Espinosa-Jeffrey R. A. Arrazola B. Chu A. Taniguchi S. M. Barajas P. Bokhoor J. Garcia A. Feria-Velasco J. de Vellis

Research Article-Integrative Molecular Medicine (IMM)

June 25, 2016

Edna Aurelus

Research Article-Integrative Molecular Medicine (IMM)

July 07, 2016

Estela S. Estap

Commentary-Integrative Molecular Medicine (IMM)

July 07, 2016

Ricardo H. Alvarez Cancer Treatment Centers of America

Submission date: November 30, 2016 Publication date: January 31, 2017

Editor Affiliation: David W. Moskowitz MD FACP, Founder and CEO, GenoMed, Inc. (www.genomed.com)

Submission date: June 30, 2016 Publication date: August 03, 2016

Description of the Special Issue: It's widely agreed that molecular medicine will revolutionize the practice of medicine. Few people realize that it's long overdue. Linus Pauling and colleagues published "Sickle Cell Anemia, a Molecular Disease," in the November 1949 issue of Science, but the treatment for sickle cell disease remains unsatisfactory over 65 years later.

What has been holding up the medical revolution? Papers are solicited on this general topic. They may address any of the following topics, or another that the author feels is equally important:

1. Problems solving polygenic diseases 2. Is there a better approach to oncology? 3. Drug discovery and development in the 21st century 4. Shifting the healthcare industry to prevention: economic and legal challenges 5. The role of public health authorities 6. The role of the media 7. The role of investors

View original post here:
Molecular Medicine | Molecular Medicine Reports ...